Want to see UPC full AI Analyst Report?
Top Page
Universe Pharmaceuticals
(NASDAQ:UPC)
Select Model
Select Model
Rating:49Neutral
Price Target:
$5.50
▲(62.24% Upside)
Action:Reiterated
Date:08/05/26
The score is held down primarily by deteriorated financial performance—multi-year revenue contraction, sustained losses, and negative operating/free cash flow—despite a relatively conservative balance sheet. Technicals provide some offset as the stock is trading above key moving averages with generally constructive momentum, while valuation remains challenged due to negative earnings and no dividend yield data.
Positive Factors
Conservative leverage and stable asset base
Manageable leverage and a relatively stable asset base provide financial flexibility during restructuring or investment. This lowers near-term solvency risk, although persistent losses could gradually weaken the equity cushion.
Negative Factors
Multi-year revenue contraction and sustained losses
The prolonged revenue decline indicates weakened demand, distribution, or competitive positioning rather than a temporary earnings setback. Four consecutive loss-making years show that the current business model has not yet restored sufficient scale or operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage and stable asset base
Manageable leverage and a relatively stable asset base provide financial flexibility during restructuring or investment. This lowers near-term solvency risk, although persistent losses could gradually weaken the equity cushion.
Read all positive factors
Universe Pharmaceuticals (UPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.93M
Dividend YieldN/A
Average Volume (3M)955.25K
Price to Earnings (P/E)―
Beta (1Y)2.48
Revenue Growth-8.04%
EPS Growth-100.01%
CountryUS
Employees216
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,008,313
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Universe Pharmaceuticals Business Overview & Revenue Model
Company Description
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These ...
Universe Pharmaceuticals Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.74M | 17.86M | 23.02M | 32.31M | 40.14M | 47.98M |
| Gross Profit | 6.36M | 6.30M | 6.07M | 10.32M | 21.89M | 25.33M |
| EBITDA | -1.31M | -2.92M | -7.36M | -3.18M | -6.40M | 14.20M |
| Net Income | -1.94M | -3.67M | -8.73M | -6.16M | -8.74M | 11.32M |
Balance Sheet | ||||||
| Total Assets | 71.47M | 69.30M | 67.95M | 53.29M | 59.54M | 70.14M |
| Cash, Cash Equivalents and Short-Term Investments | 29.05M | 33.59M | 29.50M | 18.50M | 18.86M | 21.80M |
| Total Debt | 9.55M | 9.26M | 7.99M | 5.48M | 3.94M | 4.33M |
| Total Liabilities | 15.82M | 13.17M | 22.45M | 13.75M | 13.10M | 11.21M |
| Stockholders Equity | 55.65M | 56.13M | 45.50M | 39.53M | 46.44M | 58.93M |
Cash Flow | ||||||
| Free Cash Flow | -12.39M | -5.40M | -9.87M | 1.08M | -1.41M | -15.59M |
| Operating Cash Flow | -11.91M | -5.05M | -9.51M | 1.12M | -1.31M | -2.06M |
| Investing Cash Flow | -2.02M | -341.81K | -361.29K | -44.17K | -3.91M | -27.06M |
| Financing Cash Flow | -6.82M | 9.73M | 33.95M | -1.39M | 3.32M | 26.58M |
Universe Pharmaceuticals Technical Analysis
Neutral
3.39
Price Trends
4.88
Positive
3.98
Positive
3.76
Positive
Market Momentum
0.16
Positive
48.29
Neutral
13.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Neutral. The current price of 3.39 is below the 20-day moving average (MA) of 5.47, below the 50-day MA of 4.88, and below the 200-day MA of 3.76, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 48.29 is Neutral, neither overbought nor oversold. The STOCH value of 13.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UPC.
Universe Pharmaceuticals Risk Analysis
Universe Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Universe Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Universe Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $40.87M | -0.87 | -17.14% | ― | -10.97% | 71.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $26.93M | -1.46 | -3.48% | ― | -8.04% | -100.01% | |
42 Neutral | $3.07M | -0.03 | -56.96% | ― | ― | ― | |
39 Underperform | $3.68M | -0.30 | 5740.28% | ― | ― | ― | |
32 Underperform | $2.24M | -0.06 | -408.33% | ― | ― | 92.53% |
* Healthcare Sector Average
UPC
Universe Pharmaceuticals
5.03
1.26
33.42%
CPHI
China Pharma Holdings
0.87
-0.51
-36.67%
RDHL
RedHill Biopharma
0.61
-0.76
-55.51%
SXTC
China SXT Pharmaceuticals
3.58
-17,996.42
-99.98%
PRFX
PainReform
0.99
-7.16
-87.80%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.44
-30.66
-89.91%
Universe Pharmaceuticals Corporate Events
Universe Pharmaceuticals Closes Patent-Rich Acquisition of Best Praise International Limited
Jul 31, 2026
On June 30, 2026, Universe Pharmaceuticals completed the acquisition of Best Praise International Limited, a company that holds five patents in China for pharmaceutical compounds and drug delivery technologies targeting age-related, neurodegenerat...
Universe Pharmaceuticals Reports Interim Results and Capital Structure Changes for Six Months Ended March 31, 2026
Jul 29, 2026
Universe Pharmaceuticals Inc. is a China-based pharmaceutical manufacturer and distributor headquartered in Ji’an, Jiangxi, that serves both domestic and international markets as a foreign private issuer listed in the U.S. Its operations are...
Universe Pharmaceuticals Moves to Acquire Best Praise Patents in All-Stock Deal
Jun 26, 2026
On June 17, 2026, Universe Pharmaceuticals Inc. entered into a share purchase agreement to acquire 100% of Best Praise International Limited, which holds five early-stage pharmaceutical patents in China spanning age-related diseases, neurodegenera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.